Figure 5 from FLT3/CD99 Bispecific Antibody–Based Nanoparticles for Acute Myeloid Leukemia

Treatment with fusion protein formulations significantly reduced leukemia burden in NSG mice. A–C, 2 × 10⁶ MV4-11 cells were engrafted IV into NSG mice. Mice were then treated with either A192, FLT3-A192, CD99-A192, or Co-Assembled at a dose of 250 mg/kg every other day beginning at either day 7 or day 10, ending between day 21 to 28. A and B, Peripheral blood samples, (C and D) spleen samples, and (E and F) bone marrow samples show a lower percentage of huCD45⁺ cells between A192 and all three treatment groups. G, We engrafted 2 × 10⁶ MV4-11 cells into NSG mice and treated these mice at day 8, 10, 12, 14, 16, 18, 20, and 22 post engraftment, Kaplan–Meier survival analysis shows that mice treated with Co-Assembled survived longer than mice receiving FLT3-A192 alone. Mean ± SD (n > 5).